Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Acura delays Nexafed post meth studies

You may also be interested in...



Nexafed Gains Rite Aid Sales, But Stumbles In Extraction-Proof PSE Tests

As Nexafed distribution picks up momentum, Acura hits a setback in developing a 100% extraction-resistant formulation of its PSE decongestant. Rite Aid, the first national drug store chain to carry Nexafed, is selling only tamper-deterrent, single-ingredient PSE formulations in West Virginia and will consider making the change in other states.

Nexafed Gains Rite Aid Sales, But Stumbles In Extraction-Proof PSE Tests

As Nexafed distribution picks up momentum, Acura hits a setback in developing a 100% extraction-resistant formulation of its PSE decongestant. Rite Aid, the first national drug store chain to carry Nexafed, is selling only tamper-deterrent, single-ingredient PSE formulations in West Virginia and will consider making the change in other states.

Acura To Launch Nexafed PSE Despite Limits Of Extraction Resistance

The spread of “one-pot” meth manufacturing will not deter Acura Pharmaceuticals from launching its OTC extraction-resistant PSE product, Nexafed. Making PSE products available in an extraction-resistant delivery formulation could offer an alternative to moving all dosages of the ingredient to the Rx class.

Related Content

UsernamePublicRestriction

Register

PS105369

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel